[Uterine sarcoma. Analytic study of 37 cases]

Area of Science:

• Gynecologic Oncology
• Surgical Pathology
• Cancer Genomics

Context:

• Uterine sarcomas exhibit diverse clinical presentations and lack uniform nomenclature, complicating classification and treatment.
• These rare tumors represent 3-5% of all uterine cancers, with an incidence of 1.7 per 100,000 women.
• Associated clinical factors include obesity, hypertension, and prior pelvic radiation exposure.

Purpose:

• To analyze the clinical characteristics, management, and outcomes of uterine sarcoma cases.
• To evaluate the efficacy of adjuvant therapies (radiotherapy and chemotherapy) in improving survival rates.
• To identify genomic alterations associated with uterine sarcoma initiation and progression.

Summary:

• A retrospective analysis of 37 uterine sarcoma cases revealed leiomyosarcomas as the most common subtype (51.3%).
• Abnormal uterine bleeding was a significant clinical presentation, often detected in early stages (Ia and IIa).
• The overall failure rate was 45.1% at two years, with common metastatic sites including the lungs, liver, and breast.

Impact:

• The findings suggest that adjuvant radiotherapy and chemotherapy do not significantly enhance survival for uterine sarcoma subtypes when added to hysterectomy.
• This study underscores the need for standardized nomenclature and further research into effective therapeutic strategies for uterine sarcomas.
• Understanding genomic alterations in chromosomes 1, 7, and 11 may offer future targets for therapeutic intervention.